Promising Growth Outlook for scPharmaceuticals Driven by Furoscix Expansion and Strong Market Demand

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on scPharmaceuticals (SCPH – Research Report), with a price target of $25.00.

Stacy Ku has given her Buy rating due to a combination of factors that highlight the promising outlook for scPharmaceuticals. The launch of Furoscix has shown strong patient demand, particularly with the expansion into Class IV heart failure and chronic kidney disease (CKD) markets. This expansion is expected to drive further growth and adoption, supported by improved payor coverage and more affordable copays, which are crucial for increasing prescriptions.
Additionally, the company has made significant efforts in training and education, resulting in a growing number of healthcare providers prescribing Furoscix. The increase in prescriber numbers and integrated delivery network purchases indicates a solid demand for the product. The momentum is further supported by the expansion of the sales force, targeting new prescribers and supporting early adopters. These factors, combined with positive feedback on Furoscix’s efficacy and tolerability, underpin Stacy Ku’s confidence in the stock’s potential for growth.